Determination of low levels of benzodiazepines and their metabolites in urine by hollow-fiber liquid-phase microextraction (LPME) and gas chromatography–mass spectrometry (GC–MS)

Selective Extraction of Diazepam and Its Metabolites from Urine Samples by a Molecularly Imprinted Solid-Phase Extraction (MISPE) Method

In this research, a molecularly imprinted polymer (MIP) was synthesized by precipitation polymerization using oxazepam (OZ) as a template molecule and was subsequently applied as a selective sorbent for the extraction of diazepam (DZP) and its metabolites in urine samples using an SPE cartridge. OZ, temazepam (TZ), nordiazepam (NZ) and DZP were analyzed in the final extracts by high-performance liquid chromatography with diode array detection (HPLC-DAD). The SPE extraction steps were optimized, and the evaluation of an imprinting factor was carried out. The selectivity of the method for OZ versus structurally related benzodiazepines (BZDs), such as bromazepam (BRZ), tetrazepam (TTZ) and halazepam (HZ), was investigated. Under the optimum conditions, the proposed methodology provided good linearity in the range of 10-1500 ng/mL, with limit of detection values between 13.5 and 21.1 ng/mL and recovery levels for DZP and its metabolites from 89.0 to 93.9% (RSD ≤ 8%) at a concentration level of 1000 ng/mL. The proposed method exhibited good selectivity, precision and accuracy and was applied to the analysis of urine samples from a real case of DZP intake.

Innovative analysis of diazepam, zolpidem and their main metabolites in human urine by micelle-to-solvent stacking in capillary electrophoresis

Diazepam and zolpidem are the most widely used medications for managing insomnia. However, significant concerns regarding the potential risks of misuse and abuse problems arose in many literatures. While urine analysis is a valuable diagnostic tool, a challenge arises from the fact that some parent drugs may remain undetectable in urine. This necessitates concurrent monitoring of their metabolites. Here, we described an innovative on-line sample preconcentration technique known as micelle to solvent stacking (MSS) for the analysis of diazepam, zolpidem, and their main metabolites in urine. Several key parameters warrant further discussion to optimize the MSS model, enhancing its performance in terms of sensitivity and resolution. After optimizing the conditions, we conducted a validation test, achieving high correlation coefficients (greater than 0.9977) for intra-day and inter-day regression lines. Additionally, both the relative standard deviation (RSD) and relative error (RE) remained below 6.10% and 12.55%, respectively. The limits of detection (LODs, S/N = 3) for all five analytes ranged from 2.0 to 56 ng/mL. Compared to the conventional capillary zone electrophoresis method, this new approach exhibited remarkable sensitivity enhancements, ranging from 123 to 235-fold. Upon applying this method to actual urine samples from patients, we successfully detected nordiazepam, zolpidem, and its metabolites. This simple and sensitive approach has promising applications in supporting patient medication safety and bolstering forensic investigations.

Dispersive liquid-liquid microextraction (DLLME) for determination of tricyclic antidepressants in whole blood and plasma samples and analysis by liquid chromatography with diode array detector (LC-DAD)

Microextractions have been developed for the tricyclic antidepressants (TCAs) analysis in biological matrices, including dispersive liquid-liquid microextraction (DLLME). The proposed DLLME employed 490 µL of biological sample (whole blood or plasma), which were added 15 mg of NaCl, 10 µL of medazepam as internal standard (10 µg/mL) and 100 µL of 2 M NaOH. This mixture was homogenized by vortex (2800 rpm/10 s) and 400 µL of hexane (extractor solvent) with 600 µL of methanol (dispersing solvent) were added to the sample. After the vortex step (2800 rpm/5 s), an ultrasonic bath for 300 s was employed. Then, this content was centrifuged (10 min/10000 rpm), organic phase was collected and dried under air flow. After, 30 µL of the mobile phase was used for resuspension and 20 µL is injected into LC-DAD. This method was optimized and fully validated according to UNODC and SWGTOX guidelines, reaching limits of detection equivalent to analytical methodologies that employ mass spectrometry (MS). Also, it was applied in real cases involving suspected exposure to TCAs. So, the developed DLLME for the determination of TCAs in whole blood and plasma samples proved to be a simple, reliable, robust and reproducible method that can be used in toxicology and clinical laboratories.

Simultaneous determination of the four key fluoroquinolones and two antipsychotics in fish and shrimp by LC-MS/MS

In this study, we developed and validated a liquid chromatography triple quadrupole tandem mass spectrometry (LC-MS/MS) method used to simultaneously determine levels of four fluoroquinolones (ofloxacin, norfloxacin, lomefloxacin, and pefloxacin) and two antipsychotics (diazepam and methaqualone) in fish and shrimp. The samples were extracted with a mixture of anhydrous sodium sulfate and acetonitrile, and purified by C₁₈ cartridge solid-phase extraction with an optimized eluent. The MS² method was applied to recognize the molecular structure of these compounds according to a main fragmentation scheme. The key ions of identification and quantification were deduced from chemical structures. Multiple reaction monitoring was used to quantitatively analyse the compounds of interest. Satisfactory linearities were obtained (R² ≥0.99) with the limits of quantitation (LOQs) ranging between 0.03 and 1.96 μg kg^-1. The recoveries were 74-122%, with a relative standard deviation (RSD) below 4.9% for these compounds at the spiking level of three, five, and ten times the LODs, respectively. The LC-MS/MS method allows precise and sensitive determination of residues of six important banned veterinary drugs in fish and shrimp tissue. This methodological approach solved the problem imposed by the need for two or more analysis methods to analyse the compounds of interest described in this study.

Calcium/Copper Alginate Framework Doped with CuO Nanoparticles as a Novel Adsorbent for Micro-extraction of Benzodiazepines from Human Serum

Background:

Sample preparation is one of the most challenging phases in pharmaceutical analysis, especially in biological matrices, affecting the whole analytical methodology.

Objective:

In this study, a new Ca(II)/Cu(II)/alginate/CuO Nanoparticles Hydrogel Fiber (CCACHF) was synthesized through a simple, green procedure and applied for fiber micro solid-phase extraction (FMSPE) of diazepam (DIZ) and oxazepam (OXZ) as model drugs prior to high-performance liquid chromatography-UV detection (HPLC-UV).

Methods:

Composition and morphology of the prepared fiber were characterized and the effect of main parameters on the fiber fabrication and extraction efficiency have been studied and optimized.

Results:

In optimal conditions, calibration curves were linear, ranging between 0.1–500 μg L−1 with regression coefficients of 0.9938 and 0.9968. Limit of Detection (LOD) (S/N=3) and Limit of Quantification (LOQ) (S/N=10) of the technique for DIZ and OXZ were 0.03 to 0.1 μg L−1. Within-day and between-day Relative Standard Deviations (RSDs) for DIZ and OXZ were 6.0–12.5% and 3.3–9.4%, respectively.

Conclusion:

The fabricated adsorbent has been substantially employed to the extraction of selected benzo-diazepines (BZDs) from human serum real specimens and the obtained recoveries were also satisfactory (82.1-109.7%).

Development of an easy and rapid analytical method for the extraction and preconcentration of chloroquine phosphate from human biofluids prior to GC-MS analysis

A vortex assisted spraying based fine droplet formation liquid phase microextraction (VA-SFDF-LPME) method was developed to determine chloroquine phosphate at trace levels in human serum, urine and saliva samples by gas chromatography–mass spectrometry (GC–MS) with single quadrupole mass analyzer. In the first part, several liquid phase microextraction (LPME) and magnetic solid phase extraction (MSPE) methods were compared to each other in order to observe their extraction ability for the analyte. VA-SFDF-LPME method was selected as an efficient and easy extraction method due to its higher extraction efficiency. Optimization studies were carried out for the parameters such as extraction solvent type, sodium hydroxide volume/concentration, sample volume, spraying number and mixing type/period. Tukey's method based on post hoc test was applied to all experimental data for the selection of optimum values. Optimum extraction parameters were found to be 12 mL initial sample volume, two sprays of dichloromethane, 0.75 mL of 60 g/kg sodium hydroxide and 15 s vortex. Under the optimum conditions, limit of detection and quantification (LOD and LOQ) were calculated as 2.8 and 9.2 μg/kg, respectively. Detection power of the GC–MS system was increased by approximately 317 folds with the developed extraction/preconcentration method. The applicability and accuracy of the proposed method was evaluated by spiking experiments and percent recovery results for human urine, serum and saliva samples were found in the range of 90.9% and 114.0% with low standard deviation values (1.9–9.4).

Simultaneous extraction and analysis of clozapine and lorazepam from human plasma using dual solvent-stir bar microextraction with different acceptor phases followed by high-performance liquid chromatography ultra-violet detection

A new design of dual solvent stir bar microextraction (DSSBME) was developed and combined with HPLC-UV for the simultaneous extraction of clozapine (CLZ) and lorazepam (LRP) from human plasma with different acceptor phases. Two short hollow fibers immobilized with an organic extraction solvent were used as the solvent bars for microextraction of CLZ and LRP from the sample solution. The solvent bars were fixed with a staple pin which served as the stirrer. The target analytes were simultaneously and selectively extracted from the sample solution into their corresponding solvent bar. Extraction parameters such as organic solvent type, pH of the sample solution, the acceptor phase concentration, salt incorporation into the solution, stirring rate, and extraction time were optimized to achieve the best extraction results. Under the optimum conditions (1-undecanol as extraction solvent, pH of sample solution = 9.0, 10% w/v NaCl, concentration of HCl = 10 mM, concentration of NaOH = 100 mM, stirring rate of 1400 rpm and extraction time of 30 min at ambient temperature) the limit of detection for CLZ was 0.4 ng mL^-1 and for LRP it was 1.1 ng mL^-1. The linear range for CLZ was 1.3-1000.0 ng mL^-1 (R² = 0.9991) and for LRP it was 3.6-800.0 ng mL^-1 (R² = 0.9993). Extraction recovery and the enrichment factor for CLZ were 95.4% and 343 and for LRP they were 74.3% and 263, respectively. Finally, the method developed was successfully applied for the simultaneous determination of CLZ and LRP in human plasma samples.

Supramolecular solvent (SUPRASs) extraction method for detecting benzodiazepines and zolpidem in human urine and blood using gas chromatography tandem mass spectrometry

OBJECTIVE

A high-throughput and sensitive method using supramolecular solvent (SUPRASs) for detecting 9 benzodiazepines and zolpidem in human urine and blood by gas chromatography-tandem mass spectrometry (GC-MS/MS) was newly established and applied to authentic human urine and blood samples in this study.

METHODS

Urine and blood samples were subjected to liquid-liquid extractions with supramolecular solvent mixture which consists of tetrahydrofuran and 1-hexanol. The solvent layer was evaporated to dryness by stream of nitrogen. The residue was reconstituted with methanol, and subjected to analysis by GC-MS/MS in multiple reaction monitoring (MRM) mode; internal standard method was employed for quantifying of each targeted compound.

RESULTS

The regression equation has a good linear relationship with correlation coefficients for all tested compounds were not lower than 0.9991. The lower limits of the quantification ranged from 0.20 to 5 ng/mL for tested compounds in urine; Meanwhile, the lower limits of the quantification in this method ranged from 1 to 50 ng/mL for tested compounds in blood. These results showed that excellent reproducibility and satisfactory extraction recovery rates could be obtained for the established analytical method for 10 drugs in both blood and urine samples.

CONCLUSION

The established method in this study was high-throughput, simple and sufficiently sensitive for determining of benzodiazepinesand zolpidem in human urine and blood. Therefore, this newly established method could be of use for qualitative and quantitative determination of such drugs in urine and blood samples either for clinical poisoning monitoring or for forensic identification.

MASS SPECTROMETRY ANALYSIS OF DRUGS OF ABUSE: CHALLENGES AND EMERGING STRATEGIES

Mass spectrometry has been the "gold standard" for drugs of abuse (DoA) analysis for many decades because of the selectivity and sensitivity it affords. Recent progress in all aspects of mass spectrometry has seen significant developments in the field of DoA analysis. Mass spectrometry is particularly well suited to address the rapidly proliferating number of very high potency, novel psychoactive substances that are causing an alarming number of fatalities worldwide. This review surveys advancements in the areas of sample preparation, gas and liquid chromatography-mass spectrometry, as well as the rapidly emerging field of ambient ionization mass spectrometry. We have predominantly targeted literature progress over the past ten years and present our outlook for the future. © 2020 Periodicals, Inc. Mass Spec Rev.

Accurate quantification of EVT201 and its two metabolites in human urine using UHPLC-MS/MS method with solid phase extraction

A sensitive and accurate ultra-high performance liquid chromatography-tandem mass spectrometry (UHPLC-MS/MS) method was developed and validated for the determination of EVT201 and its two metabolites, Ro46-1927 and Ro18-5528, in human urine. Different sample preparation methods were compared, and solid-phase extraction (SPE) was finally employed. Separation conditions and mass spectrometry parameters were optimized to achieve complete separation and enough sensitivity. Finally, the three analytes were separated on an Acquity BEH C18 column (2.1 mm × 50 mm, 1.7 μm) with a gradient mobile phase. The gradient elution consisted of acetonitrile (containing 0.1% formic acid) and 10 mM ammonium formate (containing 1% acetonitrile and 0.1% formic acid) at a flow rate of 0.50 mL/min. Detection was performed on an electrospray ionization (ESI) source in positive mode with multiple reaction monitoring (MRM). The method was fully validated in accordance with the bioanalysis guidance in Chinese Pharmacopoeia. It showed satisfying linearity, accuracy, and precision in the range of 0.2–200 ng/mL for all the three analytes. The mean extraction recoveries were 85.2%, 65.6%, 87.9%, and 86.4% for EVT201, Ro46-1927, Ro18-5528, and the IS, respectively. The method was successfully applied to the bioanalysis of 833 urine samples to determine the concentration of EVT201 and its two metabolites simultaneously.

Layered double hydroxide nanoparticles embedded in a biopolymer: a novel platform for electroanalytical determination of diazepam

A Co–Al layered double hydroxide/poly(tyrosine) modified glassy carbon electrode was prepared and used for electrocatalytic determination of diazepam in real samples.

Hollow-fiber renewal liquid membrane extraction coupled with 96-well plate system as innovative high-throughput configuration for the determination of endocrine disrupting compounds by high-performance liquid chromatography-fluorescence and diode array detection

This paper describes a new configuration of the hollow fiber renewal liquid membrane (HFRLM) procedure for the high-throughput determination of the endocrine disrupting compounds 4-nonylphenol, 4-octylphenol, 4-tert-octylphenol, methylparaben, ethylparaben and bisphenol A using a 96-well plate system and high-performance liquid chromatography. In this configuration, cylindrical blades were adapted as a support for polypropylene membranes used as supported liquid membranes in the HFRLM approach. The proposed configuration exhibited important advantages including high-throughput, low solvent and sample consumption, and good analytical performance. The optimized extraction conditions were achieved with the use of a mixture comprised of 50:50 v/v 1-octanol:hexane as the supported liquid membrane, sample pH 5, extraction solvent 15 μL (hexane) and extraction time 45 min. The limits of quantification varied from 0.5 μg L^-1 for 4-octylphenol to 15 μg L^-1 for methylparaben and ethylparaben and the r² ranged from 0.9908 for methylparaben to 0.9992 for 4-tert-octylphenol. HFRLM combined with the use of a 96-well plate provides an environmentally-friendly configuration. It offers good accuracy when applied to analyze water samples, with relative recoveries ranging from 72 to 130%, for 4-octylphenol and 4-nonylphenol, respectively, and precision varying from 1 to 14.3%, for 4-nonylphenol at 1.0 μg L^-1 and bisphenol A at 8.0 μg L^-1, respectively.

Rapid determination of designer benzodiazepines, benzodiazepines, and Z-hypnotics in whole blood using parallel artificial liquid membrane extraction and UHPLC-MS/MS

Benzodiazepines (BZD) and Z-hypnotics are frequently analyzed in forensic laboratories, and in 2012, the designer benzodiazepines (DBZD) emerged on the illegal drug scene. DBZD represent a particular challenge demanding new analytical methods. In this work, parallel artificial liquid membrane extraction (PALME) is used for sample preparation of DBZD, BZD, and Z-hypnotics in whole blood prior to UHPLC-MS/MS analysis. PALME of BZD, DBZD, and Z-hypnotics was performed from whole blood samples, and the analytes were extracted across a supported liquid membrane (SLM) and into an acceptor solution of dimethyl sulfoxide and 200 mM formic acid (75:25, v/v). The method was validated according to EMA guidelines. The method was linear throughout the calibration range (R² > 0.99). Intra- and inter-day accuracy and precision, as well as matrix effects, were within the guideline limit of ± 15%. LOD and LLOQ ranged from 0.10 to 5.0 ng mL^-1 and 3.2 to 160 ng mL^-1, respectively. Extraction recoveries were reproducible and above 52%. The method was specific, and the analytes were stable in the PALME extracts for 4 and 10 days at 10 and - 20 °C. No carry-over was observed within the calibration range. PALME and UHPLC-MS/MS for the determination of DBZD, BZD, and Z-hypnotics in whole blood are a green and low-cost alternative that provides high sample throughput (96-well format), extensive sample clean-up, good sensitivity, and high reproducibility. The presented method is also the first method incorporating analysis of DBZD, BZD, and Z-hypnotics in whole blood in one efficient analysis. Graphical abstract.

Preparation of a magnetic molecularly imprinted polymer for the selective adsorption of chlordiazepoxide and its determination by central composite design optimized HPLC

Core–shell magnetic molecularly imprinted polymer nanoparticles (MMIP-NPs) were prepared and applied in the extraction of chlordiazepoxide from various samples.

Salicylic acid determination in estuarine and riverine waters using hollow fiber liquid-phase microextraction and capillary zone electrophoresis

A low-cost methodology using hollow fiber liquid-phase microextraction (HF-LPME) and capillary zone electrophoresis (CZE) with UV-Vis detector was developed to analyze the salicylic acid (SA) in estuarine and riverine waters. The technique is easy-to-use and rapid, and demands little volume of organic solvent. The extraction was carried out using a polypropylene membrane supporting into octan-1-ol. HF-LPME under optimized conditions (donor solution sample pH 2, acceptor solution pH 14, sample volume 25 mL, fiber length 10 cm, acceptor volume 25 μL, extraction time 3 h and stirring speed 350 rpm) presented high enrichment factor (407 times) and good recovery in real water samples (from 88 to 110%). A limit of detection of 2.6 μg L^-1 was achieved using CZE with UV-Vis detector as quantification method. The method was applied to direct quantification of SA in environmental complex estuarine and riverine water matrices.

Development of Hollow-Fiber Liquid-Phase Microextraction Method for Determination of Urinary trans,trans-Muconic Acid as a Biomarker of Benzene Exposure

For the first time, hollow-fiber liquid-phase microextraction combined with high-performance liquid chromatography–ultraviolet was used to extract trans,trans-muconic acid, in urine samples of workers who had been exposed to benzene. The parameters affecting the metabolite extraction were optimized as follows: the volume of sample solution was 11 mL with pH 2, liquid membrane containing dihexyl ether as the supporter, 15% (w/v) of trioctylphosphine oxide as the carrier, the time of extraction was 120 minutes, and stirring rate was 500 rpm. Organic phase impregnated in the pores of a hollow fiber was extracted into 24 µL solution of 0.05 mol L⁻¹ Na₂CO₃ located inside the lumen of the fiber. Under optimized conditions, a high enrichment factor of 153–182 folds, relative recovery of 83%–92%, and detection limit of 0.001 µg mL⁻¹ were obtained. The method was successfully applied to the analysis of ttMA in real urine samples.

Dispersive liquid–liquid microextraction with back extraction using an immiscible organic solvent for determination of benzodiazepines in water, urine, and plasma samples

A novel DLLME method with a back extraction step using two immiscible organic solvents for obtaining higher clean-up than the conventional DLLME method.

Dispersive suspended-solidified floating organic droplet microextraction of nonsteroidal anti-inflammatory drugs: comparison of suspended droplet-based and dispersive-based liquid-phase microextraction methods

A dispersive suspended-solidified floating organic droplet microextraction method was developed for determination of some nonsteroidal anti-inflammatory drugs in human plasma and urine samples.